Oxidative stress in benign prostatic hyperplasia and prostate cancer

Urologia Internationalis

Volumn 85, Issue 3, 2010, Pages 328-333

  Pace, Gianna ^a,b   Di Massimo, Caterina ^a   De Amicis, Daniela ^a   Corbacelli, Carlo ^a   Di Renzo, Laura ^c   Vicentini, Carlo ^a,b   Miano, Lucio ^d   Tozzi Ciancarelli, Maria Giuliana ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Mazzini Hospital   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Benign prostatic hyperplasia; Oxidative markers; Oxidative stress; Peroxides; Plasma oxidized LDL; Prostate cancer; Superoxide dismutase; Total equivalent antioxidant capacity

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN; PEROXIDE; SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RADICAL RETROPUBIC PROSTATECTOMY;

AGED; ANTIOXIDANTS; CALIBRATION; COHORT STUDIES; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIDES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SUPEROXIDE DISMUTASE; UROLOGY;

EID: 78049476358     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315064     Document Type: Article

References (30)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LJ: The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479. (Pubitemid 14026148)
2. Boyle P, Ferlay J: Cancer incidence and mortality in Europe 2004. Ann Oncol 2005; 16: 481-485. (Pubitemid 40458328)
3. Rohrmann S, Roberts WW, Walsh PC, Platz EA: Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer. Prostate 2003; 55: 140-146. (Pubitemid 36444001)
4. Heidenreich A, Aus G, Bolla M, et al: EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80. (Pubitemid 350166735)
5. Hammarsten J, Högstedt B: Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151-158. (Pubitemid 32171181)
6. Hammarsten J, Högstedt B: Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high stage and high grade clinical prostate cancer. Blood Press 2004; 13: 47-55. (Pubitemid 38455847)
7. Valko M, Rhodes CJ, Moncol J, et al: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006; 160: 1-40. (Pubitemid 43227479)
8. Berger AP, Deibl M, Halpern EJ: Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologia 2005; 48: 784-789. (Pubitemid 40591237)
9. Ghafar MA, Puchner PJ, Anastasiadis AG, et al: Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep 2002; 3: 292-296.
10. Nandeesha H: Benign prostatic hyperplasia: Dietary and metabolic risk factors. Int Urol Nephrol 2008; 40: 649-656.
11. Di Massimo C, Scarpelli P, di Lorenzo N, et al: Impaired plasma nitric oxide availability and extracellular superoxide dismutase activity in healthy humans with advancing age. Life Sci 2006; 78: 1163-1167. (Pubitemid 43176709)
12. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
13. Miller NJ, Rice-Evans C, Davies MJ: A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407-421. (Pubitemid 23113948)
14. Di Massimo C, Taglieri G, Penco M, Tozzi- Ciancarelli MG: Influence of aging and excise on platelet function. Clin Hemorheol Microcirc 1999; 20: 105-110.
15. Kumar B, Koul S, Khandrika L, et al: Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008; 68: 1777-1785. (Pubitemid 351416563)
16. Aydin A, Arsova-Sarafinovska Z, Sayal A, et al: Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem 2006; 39: 176-189. (Pubitemid 43255508)
17. Tam NN, Nyska A, Maronpot RR, et al: Differential attenuation of oxidative/nitrosative injuries in early prostatic neoplastic lesions in TRAMP mice by dietary antioxidants. Prostate 2006; 66: 57-69. (Pubitemid 43005949)
18. Yamasaki M, Nomura T, Sato F, Mimata H: Metallothionein is upregulated under hypoxia and promotes the survival of human prostate cancer cells. Oncol Rep 2007; 18: 1145-1153.
19. Dogru-Abbasoglu S, Aykaç-Toker G, Koçak T, et al: Antioxidant enzymes activities and lipid peroxides in the plasma of patients with benign prostatic hyperplasia or prostate cancer are not predictive. J Cancer Res Clin Oncol 1999; 125: 402-404. (Pubitemid 29287498)
20. Bostwick DG, Alexander EE, Singh R, et al: Antioxidant enzymes expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000; 89: 123-134. (Pubitemid 30451282)
21. Sikka SC: Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention - a mechanistic approach. Curr Med Chem 2003; 10: 2679-2692.
22. Lim SD, Sun C, Lambeth JD, et al: Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 2005; 62: 200-207. (Pubitemid 40096784)
23. Pennathur S, Heinecke J: Oxidative stress and endothelial dysfunction in vascular disease. Curr Diab Rep 2007; 7: 257-264. (Pubitemid 47249084)
24. Endemann DH, Schiffrin EL: Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Curr Hypertens Rep 2006; 6: 85-89.
25. Brook RD: Obesity, weight loss, and vascular function. Endocrine 2006; 29: 21-25.
26. De Marzo AM, Platz EA, Sutcliffe S, et al: Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269. (Pubitemid 46486616)
27. Olinski R, Zastawny TH, Foksinski M, et al: DNA base modifications and antioxidant enzyme activities in human benign prostatic hyperplasia. Free Radic Biol Med 1995; 18: 807-813.
28. Jung K, Seidel B, Rudolph B, et al: Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells. Free Radic Biol Med 1997; 23: 127-133. (Pubitemid 27217016)
29. Baker AM, Oberley LW, Cohen MB: Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 1997; 32: 229-233. (Pubitemid 27374193)
30. Gate L, Paul J, Nguyen Ba G, et al: Oxidative stress induced in pathologies: The role of antioxidant. Biomed Pharmacother 1990; 53: 169-180.